ライフサイエンスコーパス: type 1

1 st human 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) enzyme (IC50 3.0 nM) with >10000-fo

2 nd the switch from trivalent OPV (containing types 1, 2, and 3 poliovirus) to bivalent OPV (containin

3 ine (OPV) "switch" from trivalent OPV (tOPV; types 1, 2, and 3 polioviruses) to bivalent OPV (bOPV; t

4 ry endpoint of seroconversion for poliovirus types 1, 2, and 3 was already high for the three IPV-Al

5 The mixed prion type 1-2 and cases heterozygous for codon 129 generated

6 202, type 3); and 1/10 IPV-Al: 98.5% (n=201, type 1), 94.6% (n=193, type 2), and 99.5% (n=203, type 3

7 % (n=204, type 3); 1/5 IPV-Al: 99.5% (n=204, type 1), 96.1% (n=197, type 2), and 98.5% (n=202, type 3

8 nisation schedule): 1/3 IPV-Al 98.5% (n=202, type 1), 97.6% (n=200; type 2), and 99.5% (n=204, type 3

9 we identify that, in Fmr1 knockout neurons, type 1 adenylyl cyclase (Adcy1) mRNA translation is enha

10 one important gene, angiotensin II receptor type 1 (AGTR1), in the Ca2+/AT-IIR/alpha-AR signaling pa

11 Treated eyes had more type 1 and 3 seeds.

12 Herpes simplex virus type 1 and Alzheimer's disease: possible mechanisms and

13 slices, and hippocampal cannabinoid receptor type 1 and brain-derived neurotrophic factor (BDNF) prot

14 odels with DCM, including myotonic dystrophy type 1 and CELF1 overexpression models and a myocardial

15 to be involved in elite control in human HIV type 1 and macaque SIV infections, respectively.

16 pectively enrolled and followed for incident type 1 and T2MI, and major adverse cardiovascular events

17 The incidences of both type 1 and type 2 diabetes among youths increased signif

18 xpressed on beta-cells and down-regulated in type 1 and type 2 diabetes and in infiltrating activated

19 Both type 1 and type 2 diabetes are associated with long-term

20 uate pancreatic beta cell function underlies type 1 and type 2 diabetes mellitus.

21 fects of fructose consumption in people with type 1 and type 2 diabetes mellitus.

22 ed genetic and environmental determinants of type 1 and type 2 diabetes risk and progression, as well

23 man diseases such as asthma, food allergies, type 1 and type 2 diabetes, hepatic steatosis, cardiovas

24 hronic inflammation plays a key role in both type 1 and type 2 diabetes.

25 Impaired RDD and allodynia were present in type 1 and type 2 diabetic rats but not in rats with typ

26 1050 curves of glucose concentration of type 1 and type 2 diabetics were acquired at the Departm

27 Determination of type 1 and type 2 EBV in saliva samples from people from

28 eristics and obesity and diabetes diagnoses (Type 1 and Type 2).

29 n significantly increased systemic levels of type 1 and/or type 17 cytokines and in significantly dec

30 The distinct roles of type-1 and type-2 mutations suggest their potential util

31 drial diseases and chronic disorders such as types 1 and 2 diabetes, cardiovascular disorders, and ca

32 th autism - fragile X and tuberous sclerosis types 1 and 2 syndromes.

33 gus and gastro-oesophageal junction (Siewert types 1 and 2).

34 the scrapie PrP (PrP(Sc)) grossly identified types 1 and 2.

35 nd 3 poliovirus) to bivalent OPV (containing types 1 and 3 poliovirus) called for intense global comm

36 , and 3 polioviruses) to bivalent OPV (bOPV; types 1 and 3 polioviruses) during a 2-week period in Ap

37 structurally distinct dUTPases, Dut80alpha (type 1) and DutNM1 (type 2).

38 ) IgG (26%) or antineuronal nuclear antibody type 1 (ANNA-1) IgG (also known as anti-Hu; 13%).

39 -regulatory to the classic RAS Ang II/Ang II Type 1 (AT1) receptor axis.

40 ls, and that the angiotensin (ang) II/ang II type-1 (AT1) receptor pathway may participate, together

41 iased agonist of the angiotensin II receptor type 1 (AT1R), stimulates acute catecholamine secretion

42 Klhl6-deficient type 1 B cells showed a 2-fold overexpression of genes l

43 aft carriers for the Boston Keratoprosthesis type 1 (B-KPro).

44 ong those with type 2 diabetes compared with type 1, but frequent in both groups.

45 Type 1 cannabinoid (CB1 ) receptors are widely distribut

46 rse agonist activity at cannabinoid receptor type 1 (CB1R) and inhibitory effect on inducible nitric

47 The cannabinoid receptor type 1 (CB1R) colocalized with TRPV1:tdTomato expression

48 nsmission in the PL via cannabinoid receptor type 1 (CB1R)- and 2-arachidonoylglycerol-dependent inhi

49 patients with congenital myotonic dystrophy type 1 (CDM1) and spinal muscular atrophy (SMA) patients

50 with iSS, whom we classified into 2 groups: type 1 (classical) and type 2 (secondary) iSS.

51 Type 1 (classical) iSS, defined using simple radiologica

52 severe traumatic brain injury (Barell Matrix Type 1 classification, International Classification of D

53 ment, mitochondrial dysfunction, and reduced type 1 collagen secretion and alkaline phosphatase activ

54 on transfer from Mn(II) to the low-potential type 1 Cu of MnxG requires an activation step, likely fo

55 Indeed the type 1 Cu(2+) is not reduced by Mn(II) in the absence of

56 a serum (P < 0.0001), as were other T helper type 1 cytokines.

57 t the transient receptor potential vanilloid type 1-dependent increase of excitatory neurotransmissio

58 sent 10-11% of patients with newly diagnosed type 1 diabetes <18 years of age, tGADA analysis should

59 ted Kingdom, case-control study of childhood type 1 diabetes (1993-1994) in order to examine 4 exposu

60 trol Among Adolescents and Young Adults With Type 1 Diabetes (BE IN CONTROL) study was an investigato

61 pecimens from six subjects with recent-onset type 1 diabetes (T1D) and six nondiabetic matched contro

62 Type 1 diabetes (T1D) has a strong genetic component.

63 and cause selective beta cell destruction in type 1 diabetes (T1D) has focused on peptides originatin

64 selective S1PR1 agonist, CYM-5442, prevented type 1 diabetes (T1D) in the mouse Rip-LCMV T1D model.

65 Type 1 diabetes (T1D) is a chronic autoimmune disease th

66 Type 1 diabetes (T1D) is characterized by the autoimmune

67 Although type 1 diabetes (T1D) is primarily perceived as a T cell

68 Type 1 diabetes (T1D) manifests when the insulin-produci

69 -risk children prospectively followed up for type 1 diabetes (T1D) or CD.

70 7 (encoded by Tnfrsf9) deficiency suppressed type 1 diabetes (T1D) progression in NOD mice.

71 Type 1 diabetes (T1D) results from the autoimmune destru

72 autoantibodies and continue to contribute to type 1 diabetes (T1D) risk among autoantibody-positive c

73 more prevalent in type 2 diabetes (T2D) than type 1 diabetes (T1D), but the mortality risk is higher

74 lar metabolomic perturbations to humans with type 1 diabetes (T1D), we analyzed serum metabolomic pro

75 Using animal models for autoimmune type 1 diabetes (T1D), we found that CRIg(+) TRMs formed

76 e populations isolated from 81 subjects with type 1 diabetes (T1D).

77 ransgenic mice or AD transgenic animals with type 1 diabetes (T1D).

78 reactive T cell responses ultimately causing type 1 diabetes (T1D).

79 ty are early features in the pathogenesis of type 1 diabetes (T1D).

80 T cells from subjects with type 1 diabetes also exhibited lower intracellular ATP l

81 rinsic mitochondrial dysfunction observed in type 1 diabetes alters mitochondrial ATP and IFNgamma pr

82 Among patients with type 1 diabetes and at least 1 risk factor for hypoglyce

83 in a region harboring a previously reported type 1 diabetes and autoimmune disorder locus.

84 ibility complex protein associated with both type 1 diabetes and celiac disease.

85 In patients with both type 1 diabetes and end-stage renal disease, SPK recipie

86 of subsequent hypoglycemia in patients with type 1 diabetes and NAH, but does not in patients with I

87 of NT-ES-beta-cells for cell replacement for type 1 diabetes and provide proof of principle for thera

88 larly difficult for both the individual with type 1 diabetes and the health-care provider.

89 istent hypertension in three mouse models of type 1 diabetes and two models of type 2 diabetes by ade

90 8,676 children at increased genetic risk of type 1 diabetes at six sites in the U.S. and Europe.

91 variants in larger numbers of subjects with type 1 diabetes characterized for a wider range of cross

92 31-60 years, the clinical characteristics of type 1 diabetes differed from those of type 2 diabetes:

93 The majority of individuals with type 1 diabetes do not meet recommended glycemic targets

94 The inability to manage type 1 diabetes effectively during these years is associ

95 te persons aged 8 years or older who had had type 1 diabetes for at least 2 years and had an HbA1c le

96 non-HLA gene polymorphisms identified by the Type 1 Diabetes Genetics Consortium (T1DGC).

97 ard ratio [HR], 1.00; 95% CI, 0.86-1.16) and type 1 diabetes in childhood.

98 randomised controlled trial, 75 adults with type 1 diabetes in the CGM group of the DIAMOND trial we

99 k of atrial fibrillation in individuals with type 1 diabetes increased with worsening glycaemic contr

100 Type 1 diabetes is a challenging condition to manage for

101 Type 1 diabetes is a T cell-mediated autoimmune disease

102 Use of CGM during pregnancy in patients with type 1 diabetes is associated with improved neonatal out

103 Type 1 diabetes is characterized by the loss of insulin

104 Type 1 diabetes is typically considered a disease of chi

105 rhesus factor), while incorporating previous type 1 diabetes knowledge.

106 ices were tested in each of 12 patients with type 1 diabetes mellitus in a clinical set-up for 12h.

107 -mediated beta-cell dysfunction and death in type 1 diabetes mellitus, although the mechanisms are in

108 s for an improved treatment of patients with type 1 diabetes mellitus.

109 promising target for beta-cell protection in type 1 diabetes mellitus.

110 n and glucose homeostasis in both type 2 and type 1 diabetes mouse models.

111 We recently reported that insulitis in type 1 diabetes of mice and humans is preceded by intrai

112 not been extensively studied in persons with type 1 diabetes or type 2 diabetes.

113 In human type 1 diabetes pancreatic islets, fasting conditions re

114 nd type 2 diabetic rats but not in rats with type 1 diabetes receiving insulin supplementation that d

115 for infants with genetic susceptibility for type 1 diabetes reduced the cumulative incidence of diab

116 Type 1 diabetes requires major lifestyle changes and car

117 o investigate the frequency and phenotype of type 1 diabetes resulting from high genetic susceptibili

118 uce hypoglycemia and glycemic variability in type 1 diabetes subjects with severe hypoglycemia.

119 Type 1 diabetes treated with insulin pump therapy or wit

120 aily injections (MDI) to CSII in adults with type 1 diabetes using CGM.

121 ous insulin infusion; CSII) in patients with type 1 diabetes using continuous glucose monitoring (CGM

122 , this bias in the clonal iNKT repertoire in type 1 diabetes was associated with increased GM-CSF, IL

123 ceptibility genotypes for celiac disease and type 1 diabetes were followed up for up to 20 years for

124 characteristics of the group diagnosed with type 1 diabetes when aged 30 years or younger.

125 characteristics of the group diagnosed with type 1 diabetes when aged 31-60 years were similar to th

126 on exercise management for individuals with type 1 diabetes who exercise regularly, including glucos

127 Among adults with type 1 diabetes who used multiple daily insulin injectio

128 n glycaemia and hypoglycaemia in adults with type 1 diabetes who were living at home and participatin

129 United States that included 158 adults with type 1 diabetes who were using multiple daily insulin in

130 Among patients with type 1 diabetes, absolute changes during the study perio

131 tation is a promising clinical treatment for type 1 diabetes, but success is limited by extensive bet

132 ement and improve glycaemia in patients with type 1 diabetes, but whether it has cardiovascular benef

133 cally investigated pleiotropy between PD and type 1 diabetes, Crohn disease, ulcerative colitis, rheu

134 Among adolescents and young adults with type 1 diabetes, daily financial incentives improved glu

135 Among adolescents with type 1 diabetes, rapid increases in albumin excretion du

136 impaired awareness of hypoglycemia (IAH) in type 1 diabetes, the capacity to transport lactate into

137 ucagon activity is blocked in the setting of type 1 diabetes, the plasma ghrelin level rises, prevent

138 nt and repertoire generation are abnormal in type 1 diabetes, which suggest that short CDR3s increase

139 ion reduced the cytotoxicity of human-origin type 1 diabetes-relevant autoreactive CD8(+) T cells.

140 Childhood-onset type 1 diabetes.

141 rol in patients with inadequately controlled type 1 diabetes.

142 children, adolescents, and young adults with type 1 diabetes.

143 for antigen specific immunotherapy (ASI) of type 1 diabetes.

144 tylated in OVE26 mice, a transgenic model of type 1 diabetes.

145 During follow-up, 1999 children developed type 1 diabetes.

146 children, adolescents, and young adults with type 1 diabetes.

147 imize the effect of immune interventions for type 1 diabetes.

148 s maintain normoglycemia in a mouse model of type 1 diabetes.

149 on with a strong agonist insulin mimetope in type 1 diabetes.

150 his hypothesis using the NOD murine model of type 1 diabetes.

151 was more similar to type 2 diabetes than to type 1 diabetes.

152 cy as it occurs in the pathological state of type-1 diabetes as well as during islet transplantation.

153 abolic imbalance in chronic diseases such as type-1 diabetes may lead to detectable perturbations in

154 Similarly, adrenalectomized type 1 diabetic (T1D) rats exhibited decreased rates of

155 cZAAV-treated counterparts, ReninAAV-treated type 1 diabetic Akita/129 mice exhibited a substantial i

156 tective action of orally administered CrP in type 1 diabetic apolipoprotein E-deficient (ApoE(-/-)) m

157 cular composition of RSSC components between type-1 diabetic and non-diabetic individuals.

158 mulation rate and the composition of RSSC in type-1 diabetic patients with those in matched controls

159 Myotonic dystrophy type 1 (DM1) is a CTG microsatellite expansion (CTG(exp)

160 Myotonic dystrophy Type 1 (DM1) is a rare genetic disease caused by the exp

161 Myotonic dystrophy type 1 (DM1) is the most common form of adult-onset musc

162 Thrombospondin type 1 domain-containing 7A (THSD7A) is a target for aut

163 ase A2 receptor 1 (PLA2R) and thrombospondin type 1 domain-containing 7A (THSD7A).

164 ipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) are the two major a

165 ated with the human disorder Episodic Ataxia Type-1 (EA1), characterized by stress-induced ataxia, my

166 e 2 strains of Epstein-Barr virus (EBV), EBV type 1 (EBV-1) and EBV-2, differ in latency genes, sugge

167 Equine herpesvirus type 1 (EHV1), a well-known member of the alphaherpesvir

168 In the multivariable analysis, type 1 electrocardiogram with syncope (hazard ratio: 4.9

169 with susceptibility to herpes simplex virus type 1 encephalitis (HSE).

170 lliance data, and then computing BDA-optimal type 1 error rates and sample sizes for oncology RCTs.

171 asso-AL) to select the penalty parameter for type-1-error control, residual bootstrap (Lasso-RB), mod

172 passed fibre size variation, predominance of type 1 fibre and centralized nuclei.

173 ticipants with type 2 diabetes vs those with type 1 had significantly higher odds of diabetic kidney

174 heterozygous mouse model of episodic ataxia type 1 harboring a dominant Kv1.1 mutation had a similar

175 ld effectiveness and safety in patients with type 1 hepatorenal syndrome.

176 ed controlled trials done in 739 adults with type 1 hepatorenal syndrome.

177 onducted by human ether-a-go-go-related gene type 1 (hERG1) channels is a major determinant of action

178 mune control of human immunodeficiency virus type 1 (HIV) infection is typically associated with effe

179 Although the human immunodeficiency virus type 1 (HIV-1) CA carboxy-terminal domain (CTD) is essen

180 The human immunodeficiency virus type 1 (HIV-1) capsid protein is an attractive therapeut

181 Human immunodeficiency virus type 1 (HIV-1) drug resistance genotyping is recommended

182 Human immunodeficiency virus type 1 (HIV-1) entry into cells is mediated by the viral

183 c groove of the human immunodeficiency virus type 1 (HIV-1) gp41 NHR trimer has been known as the cla

184 setting of high human immunodeficiency virus type 1 (HIV-1) infection and tuberculosis coprevalence.

185 persist during human immunodeficiency virus type 1 (HIV-1) infection despite effective antiretrovira

186 ts with chronic human immunodeficiency virus type 1 (HIV-1) infection.

187 Human immunodeficiency virus type 1 (HIV-1) is the result of cross-species transmissi

188 ins (Envs) from human immunodeficiency virus type 1 (HIV-1) mediate viral entry.

189 inority variant human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase inhib

190 Full-length human immunodeficiency virus type 1 (HIV-1) RNA serves as the genome or as an mRNA, o

191 HIV type 1 (HIV-1) RNA was measured in paired SP and blood p

192 maintenance of human immunodeficiency virus type 1 (HIV-1) suppression.

193 (LRAs) enhances human immunodeficiency virus type 1 (HIV-1) transcription in vivo but leads to only m

194 s immunogens in human immunodeficiency virus type 1 (HIV-1) vaccine development programs.

195 antage of the proteolytic maturation of HIV, type 1 (HIV-1), which can generate free fluorescent prot

196 ss-sectional study of matrix turnover in HIV type 1 (HIV-1)-infected and -uninfected TB patients and

197 ody may improve human immunodeficiency virus type 1 (HIV-1)-specific immunity and increase clearance

198 ng the replication of pathogens such as HIV, type 1 (HIV-1).

199 The human immunodeficiency virus type 1 (HIV-1)/simian immunodeficiency virus (SIV) envel

200 Human parainfluenza virus type 1 (HPIV1) also causes severe pediatric respiratory

201 uated a version of human parainfluenza virus type 1 (HPIV1) bearing a stabilized attenuating mutation

202 t factor in immunopathogenesis of ocular HSV type 1 (HSV-1) infection.

203 HSV type 1 (HSV-1) is a prevalent human pathogen that infect

204 ivery from mothers with herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2) genital infection.

205 TANCE Like all viruses, herpes simplex virus type 1 (HSV-1) reproduction relies upon numerous host en

206 o genome engineering of herpes simplex virus type 1 (HSV-1), which has a large DNA genome, using synt

207 rt for the concept that herpes simplex virus type 1 (HSV1), when present in the brains of apolipoprot

208 Human T-cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T-cell

209 dispensable for human T-cell leukemia virus type 1 (HTLV-1) particle biogenesis.

210 During infection with HIV type 1, human pDCs decrease in circulation and remaining

211 otides, CpG-A appears restricted to inducing type 1 IFN in innate immune cells and CpG-B to activatin

212 Type 1 IFNs, including the IFN-alphas and IFN-beta, acti

213 for two components of IL1beta signaling, the type 1 IL1 receptor or the receptor adapter protein MyD8

214 1beta and IL-18 production, lowered T-helper type-1 immune responses, and reduced atherosclerotic pla

215 To drive type 1 immunity in CNS tissues, we infected GL261 tumor-

216 tion-inducing hormone receptors, manifesting type 1 immunity, and most unexpectedly, generating myofi

217 underlying mechanisms involved an increased type 1 inflammation and cerebral endotheliopathy, charac

218 Among the features that distinguish type 1 innate lymphoid cells (ILC1s) from natural killer

219 Our path analysis model showed that collagen type 1 intensity for MDSC-like fibrocytes was positively

220 We identify the type 1 interferon pathway as a molecular mechanism by wh

221 so investigated in A549 NPro cells where the type 1 interferon response had been attenuated.

222 l RNA synthesis and increased sensitivity to type-1-interferon inhibition.

223 Type 1 interferons (T1-IFN) are known to be a constituen

224 Infection with HIV type 1 is a major risk factor for TB, and a better under

225 report outcomes and complications of Boston type 1 keratoprosthesis (KPro) implantation in children.

226 ibitor (GM6001) to block endogenous membrane type 1 matrix metalloproteinase (MT1-MMP) activity does

227 e exhibited impaired trafficking of membrane type 1 matrix metalloproteinase (MT1-MMP) and EGF recept

228 Membrane-type 1 matrix metalloproteinase (MT1-MMP) is a membrane-

229 he encephalitis observed in mouse adenovirus type 1 (MAV-1) infection, using mice lacking the IL-1 re

230 phenotype and highlighting the importance of type 1 mechanisms in this process.

231 Type 1 mGluR5 activation increases TRPA1 receptor agonis

232 Diagnosis of type 1 MI was adjudicated by study physicians.

233 s are similar to those seen in patients with type 1 MI.

234 Type 1 MIs result spontaneously from instability of athe

235 ate transporter family Molybdate Transporter type 1 (MOT1) were identified in the model legume Medica

236 ke and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13) revolutionized our ap

237 and metalloproteinase with a thrombospondin type 1 motif, member 13) activity (>10%).

238 insulin receptor (IR) and mannose receptor C-type 1 (MR), which functions to clear endogenous mannosy

239 ic zebrafish that uses a mannose receptor, C type 1 (mrc1a) promoter to drive strong EGFP expression

240 Subsequent type 1 myocardial infarction and cardiac death were repo

241 me of index type 1 myocardial infarction, or type 1 myocardial infarction or cardiac death at 30 days

242 2; 95% confidence interval, 1.92-2.81 versus type 1 myocardial infarction).

243 were reported for a primary outcome of index type 1 myocardial infarction, or type 1 myocardial infar

244 as high risk, but with lower specificity for type 1 myocardial infarction.

245 adverse cardiovascular events as those with type 1 myocardial infarction.

246 of CNS tumors arising in individuals with NF type 1 (NF1) and NF type 2 (NF2), their pathogenic etiol

247 Children with neurofibromatosis type 1 (NF1) cancer predisposition syndrome are prone to

248 Neurofibromatosis type 1 (NF1) is a common neurogenetic disorder in which

249 Neurofibromatosis type 1 (NF1), a common genetic disorder with a birth inc

250 During mitosis, the total numbers of type 1 node proteins (cell cycle kinases Cdr1p, Cdr2p, W

251 g as it disassembles and then associate with type 1 nodes around the equator of the cell during inter

252 edicine retinal screenings for patients with type 1 or 2 diabetes and identify factors for ophthalmol

253 Type 1 or 2 diabetes was listed in the medical history f

254 orth Carolina among 1787 adult patients with type 1 or 2 diabetes who received primary care at the cl

255 d), e-ROP IMAGING (trained reader grading of type 1 or 2 ROP initiates diagnostic examinations), and

256 apy for threshold ROP, earlier treatment for type 1 or pre-threshold disease has been found to decrea

257 andomized 416 patients aged >/=25 years with type 1 or type 2 diabetes, a serum creatinine (SCr) leve

258 is not always easy to distinguish LADA from type 1 or type 2 diabetes.

259 , and in one unrelated sporadic patient with type 1 painless diabetic neuropathy and chronic itch.

260 signaling is established as the canonical or type 1 pathway for TH action.

261 tinal proprotein convertase subtilisin/kexin type 1 (Pcsk1) expression, the gene encoding PC1/3, whic

262 For example, the type 1 pilus adhesin FimH binds mannose on the bladder s

263 ion of the gene encoding the mannose-binding type 1 pilus tip protein FimH demonstrated reduced bindi

264 ng enzyme phospholipid phosphate phosphatase type 1 (PLPP1) had a 2-fold increase in endogenous LPA l

265 esence of poliomyelitis associated with wild-type 1 poliovirus in districts of Pakistan over 6-month

266 rosslinked beta C-telopeptide (betaCTX), and type 1 procollagen-N-propeptide (P1NP).

267 domain 3, which down-regulates T-helper cell type 1 proinflammatory responses and is associated with

268 y cancer relevant insulin-like growth factor type 1 receptor (IGF-1R).

269 neurons from mice lacking the muscarinic ACh type 1 receptor (M1R) exhibited enhanced neurite outgrow

270 on and internalization of the angiotensin II type 1 receptor and the beta2 adrenoceptor.

271 njury in the presence of anti-angiotensin II type 1 receptor antibody (AT1R-Ab) and anti-endothelial

272 We found that corticotropin-releasing factor type 1 receptor within the paraventricular nucleus of th

273 ressive kidney injury by inhibiting TGF-beta type 1 receptor.

274 neurons, we investigated whether cannabinoid type-1 receptor (CB1R) activation is necessary for E2 to

275 vely on neurons, and neuronal angiotensin II type 1 receptors are indispensable to this process.

276 Our data demonstrate that angiotensin II type 1 receptors promote ADAM17-mediated ACE2 shedding i

277 tter inverse agonist activity at cannabinoid type 1 receptors.

278 Type 1 regulatory T (Tr1) cells differentiate in respons

279 Type 1 regulatory T cells (Tr1 cells) are induced by int

280 Thrombospondin type 1 repeats (TSRs) occur in diverse proteins involved

281 trol mechanism for folding of thrombospondin type 1 repeats by protein O-fucosyltransferase 2 (POFUT2

282 nuated recombinant human parainfluenza virus type 1 (rHPIV1) expressing the membrane-anchored form of

283 y predicted 452 of 459 infants who developed type 1 ROP (sensitivity, 98.5%; 95% CI, 96.9%-99.3%), re

284 he potential role of anti-VEGF treatment for type 1 ROP has become a focus in recent years, but the p

285 Mice with an I4895T mutation in the type 1 ryanodine receptor/Ca(2+) release channel (RyR1)

286 Type 1 Serine/Threonine Kinase Receptors (STKR1) transdu

287 ake, mediated by scavenger receptor class B, type 1 (SR-B1).

288 The increase of type-1 ST-segment elevation correlated with AES expansio

289 s for treatment trials for Stargardt disease type 1 (STGD1) and other macular diseases are needed.

290 The type 1 taste receptor member 3 (T1R3) is a G protein-cou

291 ation with low doses of gp96 primes T helper type 1 (Th1) immune responses, whereas high-dose immuniz

292 Regulatory T type 1 (TR1) cells are potent suppressors of immune resp

293 as maintained in adults with Gaucher disease type 1 treated with eliglustat who remained in the ENCOR

294 phological subtyping of pRCC stratifies pRCC type 1 tumors with regard to OS and CSS.

295 Expression levels of 17 genes characterizing type 1, type 2, and type 17 lymphocytes were measured in

296 also examined the production of prototypical type 1, type 2, type 9, type 17, and type 22 cytokines i

297 Human immunodeficiency virus (HIV) type 1 uses the CD4 molecule as its principal receptor t

298 e challenged with monovalent oral poliovirus type 1 vaccine (mOPV1) and subsequently treated with cap

299 nd clinical characteristics among those with type 1 vs type 2 MIs, and the causes of type 2 MIs.

300 The number and proportion of type 1 vs type 2 MIs, demographic and clinical character

301 All inborn babies with type 1 zone 1 ROP at the Neonatal Intensive Care Unit of